8-K: Genprex Regains Nasdaq Listing Compliance

Genprex, Inc. has successfully regained compliance with Nasdaq's minimum stockholders' equity requirement, averting immediate delisting but entering a strict one-year monitoring period.

Summary

• Genprex, Inc. was formally notified on January 7, 2026, by the Nasdaq Hearings Panel that it has regained compliance with the Nasdaq Listing Rule 5550(b)(1).
• The rule requires a minimum stockholders' equity of $2.5 million.
• This compliance resolves a previously disclosed matter initiated on August 19, 2025, when the company was found non-compliant.
• The company will be subject to a mandatory panel monitor through January 7, 2027.
• During this one-year monitoring period, if the company again falls out of compliance with the Minimum Stockholders Equity Rule, it will not be permitted to submit a new compliance plan or be granted additional time to regain compliance.
• Instead, Nasdaq will issue a Delist Determination Letter, and the company will only have the opportunity to request a new hearing, potentially leading to delisting.

Sentiment

Score: 7

Explanation: The sentiment is positive due to regaining compliance and avoiding delisting, which is a significant relief. However, it is tempered by the strict one-year monitoring period and the lack of a 'second chance' if non-compliance recurs, indicating ongoing financial fragility.

Positives

• Regained compliance with Nasdaq's minimum stockholders' equity requirement of $2.5 million.
• Avoided immediate delisting from The Nasdaq Capital Market.

Negatives

• Subject to a mandatory one-year monitoring period until January 7, 2027.
• During the monitoring period, any future non-compliance with the Minimum Stockholders Equity Rule will result in an immediate Delist Determination Letter without a chance to submit a new compliance plan or receive additional time.

Risks

• Risk of delisting if the company fails to maintain the minimum stockholders' equity requirement of $2.5 million during the mandatory monitoring period through January 7, 2027.
• No opportunity for a compliance plan or additional time to cure a deficiency if non-compliance recurs within the monitoring period.

Future Outlook

Genprex will operate under a strict one-year mandatory monitoring period by Nasdaq until January 7, 2027. During this time, any recurrence of non-compliance with the minimum stockholders' equity rule will lead directly to a delisting determination without the usual opportunities for a compliance plan or additional time to cure the deficiency.

Management Comments

• Ryan Confer, President, Chief Executive Officer, and Chief Financial Officer, signed the report on behalf of Genprex, Inc.

Industry Context

Maintaining listing compliance with major exchanges like Nasdaq is crucial for public companies, especially smaller biotechnology firms, as it impacts their ability to raise capital and maintain investor confidence. Non-compliance often signals underlying financial challenges, and regaining compliance, while positive, highlights the ongoing scrutiny such companies face regarding their financial health.

Stakeholder Impact

• Shareholders: Avoid immediate delisting, which preserves liquidity and investment value, but face continued uncertainty due to the strict monitoring period and the risk of future delisting.
• Employees: Stability is temporarily maintained by avoiding delisting, but long-term job security could be impacted by ongoing financial health challenges.
• Creditors: Reduced immediate risk of default or bankruptcy associated with delisting, but the underlying financial condition that led to non-compliance remains a concern.

Next Steps

• Maintain compliance with the Nasdaq Minimum Stockholders Equity Rule of $2.5 million throughout the mandatory monitoring period until January 7, 2027.
• Prepare for potential new hearings with the Nasdaq Hearings Panel if non-compliance recurs during the monitoring period, as this would lead to a Delist Determination Letter.

Key Dates

Recommendation

While Genprex has successfully regained compliance with Nasdaq's minimum stockholders' equity requirement, averting an immediate delisting, the underlying financial health that led to the initial non-compliance remains a concern. The mandatory one-year monitoring period, with its strict 'no second chance' clause for the same deficiency, introduces significant ongoing risk. Investors should hold their positions and closely monitor the company's financial performance and equity levels over the next year, as any renewed non-compliance would likely trigger a swift delisting process and negatively impact share value.

Keywords

Genprex, Nasdaq compliance, stockholders equity, delisting risk, GNPX, regulatory compliance, biotechnology